Viking Therapeutics (VKTX) EBITDA (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of EBITDA data on file, last reported at -$164.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 195.89% year-over-year to -$164.1 million; the trailing twelve-month figure through Mar 2026 stood at -$502.0 million (down 191.32% YoY), and the FY2025 full-year result was -$393.3 million, down 160.63% from the prior year.
• EBITDA was little changed at -$164.1 million in Q1 2026, from -$164.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$16.2 million in Q3 2022 to a low of -$164.7 million in Q4 2025.
• A 5-year average of -$51.7 million and a median of -$34.1 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA decreased 13.45% in 2022 and sank 256.28% in 2025, its largest moves.
• Tracing VKTX's EBITDA over 5 years: stood at -$20.3 million in 2022, then plunged by 44.38% to -$29.3 million in 2023, then sank by 57.89% to -$46.2 million in 2024, then slumped by 256.28% to -$164.7 million in 2025, then grew by 0.37% to -$164.1 million in 2026.
• Business Quant data shows VKTX's EBITDA at -$164.1 million in Q1 2026, -$164.7 million in Q4 2025, and -$98.6 million in Q3 2025.